Clinical Trial Update: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety, tolerability, and immunogenicity of Pfizer's meningococcal group B vaccine Trumenba (rLP2086) in immunocompromised participants …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Trumenba (rLP2086)

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 4 | Status: COMPLETED | Results posted: 2024-10-16